PTC Therapeutics (PTCT) Peer Comparison
$60.88
$0.91
(1.52%)
As on 02-Nov-2026 16:00EST
Market cap
$5,010 Mln
Revenue (TTM)
$1,156 Mln
P/E Ratio
--
P/B Ratio
1743.3
Div. Yield
0 %
Edit
| PTC Therapeutics (PTCT) | Exelixis (EXEL) | Kymera Therapeutics (KYMR) | Caredx Inc (CDNA) | Viking Therapeutics (VKTX) | |
|---|---|---|---|---|---|
Market cap ($ Mln) |
5,010 | 16,932 | 10,811 | 4,522 | 3,479 |
Revenue ($ Mln) |
1,156 | 2,497 | 102 | 497 | -- |
Net Profit ($ Mln) |
-105.97 | 885.14 | -349.47 | 128.63 | -627.20 |
Net Margin (%) |
-9.17 | 35.45 | -341.87 | 25.86 | -- |
RoE (%) |
-- | 46.96 | -22.16 | 32.94 | -115.03 |
Price to Earnings |
-- | 20.78 | -- | 42.02 | -- |
Price-To-Book |
1,743.27 | 9.23 | 6.49 | 9.83 | 5.82 |
Income Statement ($ Mln)
| PTC Therapeutics (PTCT) | Exelixis (EXEL) | Kymera Therapeutics (KYMR) | Caredx Inc (CDNA) | Viking Therapeutics (VKTX) | |
|---|---|---|---|---|---|
|
Operating Revenue
|
1,155.55 | 2,496.86 | 102.23 | 497.40 | 0.00 |
|
Cost of Revenue
|
87.91 | 93.32 | -74.16 | 144.39 | 0.09 |
|
Gross Profit
|
1,658.90 | 2,236.43 | 39.20 | 256.57 | -0.43 |
|
Operating Expenses
|
929.29 | 1,400.14 | 583.29 | 348.88 | 648.57 |
|
Operating Profit (EBIT)
|
138.35 | 1,003.39 | -404.89 | 4.13 | -648.57 |
|
Other Income
|
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
|
Profit before Tax
|
-85.09 | 1,065.84 | -349.70 | 124.22 | -627.20 |
|
Provision for Tax
|
20.88 | 180.70 | 0.00 | -4.41 | 0.00 |
|
Profit after Tax (Net Income)
|
-105.97 | 885.14 | -349.47 | 128.63 | -627.20 |
|
Minority Interest
|
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
|
Consolidated Profit
|
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Liabilities ($ Mln)
| PTC Therapeutics (PTCT) | Exelixis (EXEL) | Kymera Therapeutics (KYMR) | Caredx Inc (CDNA) | Viking Therapeutics (VKTX) | |
|---|---|---|---|---|---|
|
Shareholder's Funds
|
-191.21 | 1,833.83 | 1,614.53 | 467.46 | 588.60 |
|
Minority Interest
|
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
|
Non-Current Liabilities
|
2,622.85 | 267.78 | 63.02 | 35.03 | 254.67 |
|
Current Liabilities
|
776.08 | 411.88 | 89.72 | 138.98 | 133.90 |
|
Total Liabilities
|
2,898.77 | 2,844.42 | 1,742.81 | 413.23 | 715.73 |
Assets ($ Mln)
| PTC Therapeutics (PTCT) | Exelixis (EXEL) | Kymera Therapeutics (KYMR) | Caredx Inc (CDNA) | Viking Therapeutics (VKTX) | |
|---|---|---|---|---|---|
|
Non-Current Assets
|
669.93 | 1,191.87 | 768.68 | 320.16 | 4.17 |
|
Current Assets
|
2,537.78 | 1,321.62 | 998.59 | 321.30 | 973.00 |
|
Total Assets
|
2,898.77 | 2,844.42 | 1,742.81 | 413.23 | 715.73 |
|
Total Debt*
|
636.03 | 162.20 | 76.60 | 29.00 | 254.69 |
|
Net Current Assets
|
0.00 | 909.75 | 908.87 | 0.00 | 839.10 |
Cashflow ($ Mln)
| PTC Therapeutics (PTCT) | Exelixis (EXEL) | Kymera Therapeutics (KYMR) | Caredx Inc (CDNA) | Viking Therapeutics (VKTX) | |
|---|---|---|---|---|---|
|
Cash From Operating Activities
|
711.20 | 884.27 | -232.89 | 42.03 | -278.69 |
|
Cash Flow from Investing Activities
|
-861.98 | 350.44 | -521.06 | 2.16 | 341.39 |
|
Cash from Financing Activities
|
331.09 | -969.59 | 990.71 | -93.39 | 76.44 |
|
Net Cash Inflow / Outflow
|
-- | -- | -- | -- | -- |
Ratios
Profitability Ratios
| PTC Therapeutics (PTCT) | Exelixis (EXEL) | Kymera Therapeutics (KYMR) | Caredx Inc (CDNA) | Viking Therapeutics (VKTX) | |
|---|---|---|---|---|---|
|
ROCE (%)
|
35.24 | 32.82 | -24.09 | -5.80 | -47.30 |
|
ROE (%)
|
-104.75 | 46.96 | -22.16 | 32.94 | -115.03 |
|
ROA (%)
|
-2.29 | 28.91 | -23.06 | 17.22 | -66.85 |
|
EBIT Margin (%)
|
9.82 | 42.02 | -341.82 | 1.35 | -- |
|
Net Margin (%)
|
-9.17 | 35.45 | -341.87 | 25.86 | -- |
|
Cash Profit Margin (%)
|
0.00 | 0.00 | 0.00 | 0.00 | -- |
Growth Ratios
| PTC Therapeutics (PTCT) | Exelixis (EXEL) | Kymera Therapeutics (KYMR) | Caredx Inc (CDNA) | Viking Therapeutics (VKTX) | |
|---|---|---|---|---|---|
|
Revenue Growth (%)
|
-35.05 | 9.12 | 133.74 | 38.94 | -- |
|
EBIT Growth (%)
|
-87.09 | 23.13 | -18.50 | 121.67 | -164.25 |
|
Net Profit Growth (%)
|
-114.10 | 30.57 | -18.42 | 111.69 | -164.20 |
|
EPS Growth (%)
|
-116.63 | 38.78 | -2.42 | 133.38 | -155.36 |
|
Book Value Growth (%)
|
-28.11 | -7.57 | 48.81 | 46.83 | -21.46 |
Valuation Ratios
| PTC Therapeutics (PTCT) | Exelixis (EXEL) | Kymera Therapeutics (KYMR) | Caredx Inc (CDNA) | Viking Therapeutics (VKTX) | |
|---|---|---|---|---|---|
|
Price / Earnings
|
8.98 | 15.79 | -21.09 | -45.11 | -11.15 |
|
Price / Book Value
|
-29.85 | 5.72 | 4.16 | 3.18 | 6.28 |
|
Dividend Yield (%)
|
-- | -- | -- | -- | -- |
|
EV/EBITDA
|
7.76 | 12.44 | -19.14 | -174.47 | -9.20 |
|
Market Cap ($ Cr)
|
-- | -- | -- | -- | -- |
Solvency Ratios
| PTC Therapeutics (PTCT) | Exelixis (EXEL) | Kymera Therapeutics (KYMR) | Caredx Inc (CDNA) | Viking Therapeutics (VKTX) | |
|---|---|---|---|---|---|
|
Debt to Equity
|
0.00 | 0.00 | 0.00 | 0.00 | 0.43 |
|
Short term debt to equity ratio
|
-0.07 | 0.00 | 0.01 | 0.02 | 0.00 |
|
Current Ratio
|
3.27 | 3.21 | 11.13 | 2.31 | 7.27 |
|
Quick Ratio
|
3.13 | 3.14 | 11.13 | 2.25 | 7.27 |
|
Interest Coverage
|
0.57 | -- | -1,279.94 | -- | -7,126.22 |
Operating Efficiency Ratios
| PTC Therapeutics (PTCT) | Exelixis (EXEL) | Kymera Therapeutics (KYMR) | Caredx Inc (CDNA) | Viking Therapeutics (VKTX) | |
|---|---|---|---|---|---|
|
Debtors to sales (%)
|
20.60 | 13.16 | 0.00 | 9.60 | -- |
|
Asset Turnover
|
0.25 | 0.82 | 0.07 | 0.67 | 0.00 |
|
Receivable days
|
35.90 | 43.48 | 8.82 | 51.56 | -- |
|
Inventory Days
|
261.74 | 96.17 | -- | 68.47 | -- |
|
Payable days
|
159.73 | 147.97 | -- | 26.19 | 26,721.72 |
|
Cash Conversion Cycle
|
137.90 | -8.32 | -- | 93.85 | -- |
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
loading...
loading...
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.
